Latest stories on SUPN
Supernus–Indivior Deal Faces Dividend Financing Risk as Citibank Term Loan Remains Uncertain
TipRanks34 · bearishm&a
Supernus (SUPN) Q3 2026 Earnings Call Transcript
The Motley Fool64 · neutralearnings
Supernus Pharmaceuticals, Inc. (SUPN) Q3 2026 Earnings Call Transcript
Seeking Alpha50 · neutralearnings
Supernus sees 2026 revenue $875M-$900M vs. prior $860M-$890M
The Fly63 · neutralearnings
Supernus reports Q3 adjusted operating earnings $55.2M vs. $41.9M last year
The Fly67 · bullishearnings
SUPERNUS PHARMACEUTICALS, INC. (SUPN) files 8-K
SEC 8-K50 · neutralgeneral
Supernus Announces Third Quarter 2026 Financial Results
GlobeNewswire67 · bullishearnings
Huron Consulting Group (HURN) to Replace Supernus Pharmaceuticals in S&P SmallCap 600 Index
GuruFocus50 · neutralgeneral
Updated Effective Date: Huron Consulting Group Set to Join S&P SmallCap 600
PR Newswire50 · neutralgeneral
Huron to replace Supernus in S&P 600 at open on November 3
The Fly50 · neutralgeneral
SUPERNUS PHARMACEUTICALS, INC. (SUPN) files 8-K
SEC 8-K42 · neutralgeneral
MSG Rangers and Huron Consulting Group to join S&P SmallCap 600
Seeking Alpha50 · neutralgeneral
Huron to replace Supernus in S&P 600 at open on November 2
The Fly42 · neutralgeneral
SUPERNUS PHARMACEUTICALS, INC. (SUPN) files 8-K
SEC 8-K50 · neutralgeneral
Supernus announces orphan drug exclusivity for ONAPGO
The Fly64 · neutralproduct/pr
Supernus Announces Orphan Drug Exclusivity for ONAPGO™ (apomorphine HCl)
Business Insider64 · neutralproduct/pr
SUPERNUS PHARMACEUTICALS, INC. (SUPN) files 8-K
SEC 8-K50 · neutralgeneral
Supernus Pharmaceuticals to Announce Third Quarter 2026 Financial Results and Host Conference Call on October 29, 2026
GlobeNewswire50 · neutralgeneral
Supernus Pharmaceuticals to Announce Third Quarter 2026 Financial Results and Host Conference Call on October 29, 2026
Business Insider50 · neutralgeneral
Supernus Pharmaceuticals: The Merger Is Priced Like A Retreat, But Reads Like A Reverse Takeover
Seeking Alpha64 · neutralm&a
SUPERNUS PHARMACEUTICALS, INC. (SUPN) files 8-K
SEC 8-K50 · neutralgeneral
Supernus price target lowered to $55 from $60 at BofA
The Fly34 · bearishanalyst
Indivior Declares $8.13 Special Cash Dividend Contingent on Supernus Merger Closing
September 17, 2026
MarketChameleon54 · neutralm&a
Supernus Pharmaceuticals to Participate in September Investor Conferences
GlobeNewswire56 · neutralgeneral